← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Adecto Pharmaceuticals, Inc.
Brookline, MA
$4,718,574
Total funding
4
Grants
Funding over time
peak $1.3M · FY2016–23$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,718,574 · 4
By mechanism
R44$4,002,084 · 2
R41$416,490 · 1
R43$300,000 · 1
Investigators at Adecto Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$1,000,000
R44 · FY2018 · CA
Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers$1,000,000
R44 · FY2023 · CA
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$1,000,000
R44 · FY2019 · CA
Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers$1,000,000
R44 · FY2022 · CA
Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers$300,000
R43 · FY2019 · CA
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$300,000
R41 · FY2016 · CA
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$63,490
R41 · FY2016 · CA
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$50,000
R41 · FY2017 · CA
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$3,000
R41 · FY2018 · CA
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer$2,084
R44 · FY2019 · CA